Arrowhead Pharmaceuticals, Inc. (LON:0HI3)

Arrowhead Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	-639.71	-599.49	-205.28	-176.06	-140.85	-84.55
Depreciation & Amortization	19.57	18.6	12.49	10.42	8.27	5.94
Loss (Gain) From Sale of Investments	0.16	0.08	-	4.43	-1.71	-0.02
Stock-Based Compensation	69.48	73.97	78.13	120.89	76.67	43.38
Other Operating Activities	30.7	18.91	12.31	2.48	0.27	0.53
Change in Accounts Receivable	-2.5	-	1.41	8.85	-9.41	-0.18
Change in Accounts Payable	10	-5.54	33	-6.59	2.63	-0.82
Change in Unearned Revenue	-	-0.87	-129.18	-112.5	223.26	-63.51
Change in Other Net Operating Assets	21.03	31.49	43.23	11.95	12.19	3.44
Operating Cash Flow	-491.28	-462.85	-153.89	-136.13	171.31	-95.8
Capital Expenditures	-80.33	-141.47	-176.74	-52.78	-23.57	-11.95
Investment in Securities	-327.67	-278.6	80.58	47.36	-118.11	-228.83
Investing Cash Flow	-408	-420.07	-96.16	-5.42	-141.68	-240.78
Long-Term Debt Issued	-	392	-	-	-	-
Net Debt Issued (Repaid)	392	392	-	-	-	-
Issuance of Common Stock	432.02	431.65	3.05	5.19	11.31	257.95
Other Financing Activities	66.87	46.87	250	60	-	-
Financing Cash Flow	890.89	870.52	253.05	65.19	11.31	257.95
Foreign Exchange Rate Adjustments	4.07	4.2	-0.12	-0.07	-0.09	0.41
Net Cash Flow	-4.33	-8.21	2.89	-76.43	40.85	-78.22
Free Cash Flow	-571.61	-604.32	-330.63	-188.91	147.75	-107.75
Free Cash Flow Margin	-22864.48%	-17018.30%	-137.34%	-77.67%	106.84%	-122.46%
Free Cash Flow Per Share	-4.60	-5.05	-3.10	-1.79	1.42	-1.07
Cash Income Tax Paid	2.76	3.74	-	0	0	-0.1
Levered Free Cash Flow	-382.8	-440.13	-251.42	-60.64	63	-78.67
Unlevered Free Cash Flow	-352.41	-419.91	-239.96	-60.64	63	-78.67
Change in Net Working Capital	-30.09	-4.67	25.72	27.61	-94.77	57.82

Source: S&P Capital IQ. Standard template. Financial Sources.